Jan232017 Anavex Life Sciences to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference January 23, 2017
Jan192017 Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017 January 19, 2017
Jan32017 Anavex Life Sciences Obtains Permanent Dismissal of All Claims in Securities Lawsuit January 3, 2017
9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease Patients. December 10, 2016
Dec82016 Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease Patients December 8, 2016
Anavex Life Sciences to Present at Annual Mental Health Parity Addiction Equity Act Roundtable at U.S. Capitol, Washington, DC December 1, 2016
Anavex Life Sciences Appoints Three Distinguished Researchers To Scientific Advisory Board November 28, 2016
Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimer’s Disease November 22, 2016
